Kura Oncology (KURA) shares have soared almost 48% in pre-market trading today after the company announced that its lead product candidate showed encouraging results in a mid-stage study. The company announced positive results from a Phase 2 clinical trial evaluating lead product candidate tipifarnib for the treatment of patients with HRAS mutation-positive solid tumors.